#SFHS2608970AOrder of 31 March 2026 setting the flat-rate amounts for medical telemonitoring activities listed in Article L. 162-52 of the Social Security Code and the financial compensation for medical telemonitoring activity in the context of early digital care by health insurance provided for in II and III of Article R. 162-117 of the Social Security Code
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
This French decree establishes fixed reimbursement rates (forfaits) that health insurance will pay for various digital medical telemonitoring (télésurveillance médicale) devices and services. The order lists specific monthly or semi-annual flat fees in euros for telemonitoring solutions used in diabetes (type 1/2 and gestational), chronic kidney disease, chronic heart failure, localized and advanced/metastatic cancer, and cardiac defibrillators or stimulators. Rates range from €38.95 to €71.93 per month depending on the condition and technology, with one semi-annual option at €304.63. These payments compensate operators or distributors providing the approved digital medical devices (DMN) listed under Article L. 162-52.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Establishes 14 specific flat-rate reimbursement codes and amounts for medical telemonitoring devices effective 13 days after official publication
- Sets monthly rate of 42.90 € for DMN-TSM diabetes type 1 and 2 under insulin
- Sets monthly rates of 48.85 € for gestational diabetes telemonitoring (three different codes)
+ 3 more changes with Pro
Obligations
What this law requires
Reimburse operators or distributors of approved digital medical telemonitoring devices at the flat-rate amounts specified in Article 1 for each condition and device code listed
Apply monthly flat-rate reimbursements ranging from €38.95 to €71.93 per patient depending on the specific digital medical device and medical condition (diabetes types 1/2, gestational diabetes, chronic kidney disease, chronic heart failure, localized/advanced cancer)
Apply semi-annual flat-rate reimbursement of €304.63 for telemonitoring devices associated with cardiac defibrillators or stimulators (code 1662186)
Ensure reimbursement amounts are calculated and applied per patient on a monthly or semi-annual basis as specified for each device code
Apply the decree effective from the thirteenth day following its publication in the Journal officiel de la République française